Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J AOAC Int ; 107(2): 286-302, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38218728

ABSTRACT

BACKGROUND: Human milk oligosaccharides (HMOs) are important components of breast milk and may be responsible for some of the benefits of breastfeeding, including resistance to infections and the development of a healthy gut microbiota. Selected HMOs are now available for addition to infant formula, and suitable methods to control the dosing rate are needed. OBJECTIVE: To develop and validate a suitable method for the analysis of HMOs in infant formula. METHOD: A method was developed for the determination of seven human milk oligosaccharides (2'-fucosyllactose, 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose (6'SL), 2',3-difucosyllactose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT)) in infant formula and adult nutritionals. The oligosaccharides are labeled at their reducing end with 2-aminobenzamide, separated by liquid chromatography and detected using a fluorescence detector. Maltodextrins are enzymatically hydrolyzed before analysis to prevent potential interference; likewise, an optional ß-galactosidase treatment can be used to remove ß-galactooligosaccharides. Fructooligosaccharides or polydextrose do not generally interfere with the analysis. RESULTS: The method has been validated in a single laboratory on infant formula and adult nutritionals. The seven HMOs were spiked into eight matrixes at three or four spike levels, giving a total of 176 data points. Recoveries were in the range of 90.9-109% in all cases except at the lowest spike level in one matrix (elemental formula), where the LNT recovery was 113%, the LNnT recovery was 111%, and the 6'SL recovery was 121%. Relative repeatabilities (RSD(r)) were in the range of 0.1-4.2%. The performance is generally within the requirements outlined in the Standard Method Performance Requirements (SMPR®) published by AOAC INTERNATIONAL. CONCLUSIONS: The method developed is suitable for the determination of seven HMOs in infant formula and demonstrated good performance during single-laboratory validation. HIGHLIGHTS: A method has been developed that is suitable for the determination of seven HMOs in infant formula.


Subject(s)
Gastrointestinal Microbiome , Milk, Human , Adult , Female , Infant , Humans , Infant Formula , Oligosaccharides , Chromatography, Liquid
2.
Clin Nutr ; 38(4): 1570-1580, 2019 08.
Article in English | MEDLINE | ID: mdl-30269898

ABSTRACT

BACKGROUND & AIMS: Protein content of a meal is hypothesized to drive DIT dose-dependently. However, no single meal study exists comparing two different doses of protein on DIT. In addition, the source of protein, particularly whey protein, was shown to have a higher DIT than casein and soy in the acute setting, however the mechanism behind this difference is not yet clear. The aim of the present work is therefore to evaluate the efficacy of two different doses and types of protein (whey protein and casein) on DIT in overweight adults. METHODS: Randomized, double blind crossover including seventeen overweight men and women assigned to four isocaloric study treatments where protein and carbohydrate were exchanged: control, 30 g of whey protein microgels (WPM30), 50 g WPM (WPM50) or 50 g micellar casein (MC50). Energy expenditure was measured by indirect calorimetry. Blood, breath and urine samples were collected in order to measure substrate oxidation, amino acid profile, glucose and insulin, protein turnover and other metabolic parameters. RESULTS: DIT was 6.7 ± 3.7%, 13.0 ± 5.0%, 18.0 ± 5.0% and 16.0 ± 5.0% for control, WPM30, WPM50 and MC50, respectively. There was a significant difference between WPM50 and WPM30 (p < 0.005) and a trend was observed between WPM50 and MC50 (p = 0.06). WPM50 resulted in the highest total, essential, and branched-chain plasma amino acid concentrations when compared with the other study treatments (p < 0.005) and a higher insulin concentration than MC50 (p < 0.005). Protein oxidation was higher for WPM50 than MC50. Protein turnover was significantly correlated with DIT through total leucine oxidation (r = 0.52, p = 0.005). CONCLUSIONS: Our findings show that DIT does increase at a dose beyond 30 g of WPM and that the type of dairy protein may have an effect on DIT with WPM tending towards a higher DIT than casein. Although further research is required to understand the mechanism behind the effect of different protein sources on thermogenesis, we suggest that amongst the components of protein turnover, protein oxidation may be an important driver of thermogenesis at doses higher than 30 g. These results have concrete implications when choosing a dose of protein to optimize its thermogenic effect. CLINICAL TRIAL REGISTRY NUMBER: NCT02303080 www.clinicaltrials.gov.


Subject(s)
Caseins/pharmacology , Overweight/metabolism , Thermogenesis/drug effects , Whey Proteins/pharmacology , Adult , Amino Acids/blood , Amino Acids/metabolism , Blood Glucose/analysis , Cross-Over Studies , Diet , Double-Blind Method , Energy Metabolism , Female , Humans , Insulin/blood , Male , Proteins/metabolism
3.
Am J Pathol ; 182(4): 1297-307, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23454183

ABSTRACT

Amyloid A amyloidosis is a protein misfolding disease characterized by deposition of extracellular aggregates derived from the acute-phase reactant serum amyloid A protein. If untreated, amyloid A amyloidosis leads to irreversible damage of various organs, including the kidneys, liver, and heart. Amyloid A deposits regress upon reduction of serum amyloid A concentration, indicating that the amyloid can be efficiently cleared by natural mechanisms. Clearance was proposed to be mediated by humoral immune responses to amyloid. Here, we report that amyloid clearance in mice lacking complement factors 3 and 4 (C3C4(-/-)) was equally efficient as in wild-type mice (C57BL/6), and was only slightly delayed in agammaglobulinemic mice (J(H-/-)). Hence, antibodies or complement factors are not necessary for natural amyloid clearance, implying the existence of alternative physiological pathways for amyloid removal.


Subject(s)
Complement System Proteins/metabolism , Immunoglobulins/metabolism , Serum Amyloid A Protein/metabolism , Agammaglobulinemia/metabolism , Agammaglobulinemia/pathology , Amyloidosis/metabolism , Amyloidosis/pathology , Animals , Antigens, Surface/metabolism , Disease Progression , Endocytosis/drug effects , Endopeptidase K/pharmacology , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver/ultrastructure , Macrophages/drug effects , Macrophages/metabolism , Macrophages/pathology , Macrophages/ultrastructure , Mice , Mice, Inbred C57BL , Milk Proteins/metabolism , Spleen/drug effects , Spleen/metabolism , Spleen/pathology
4.
PLoS Pathog ; 8(8): e1002867, 2012.
Article in English | MEDLINE | ID: mdl-22912582

ABSTRACT

Neuroinvasion and subsequent destruction of the central nervous system by prions are typically preceded by a colonization phase in lymphoid organs. An important compartment harboring prions in lymphoid tissue is the follicular dendritic cell (FDC), which requires both tumor necrosis factor receptor 1 (TNFR1) and lymphotoxin ß receptor (LTßR) signaling for maintenance. However, prions are still detected in TNFR1⁻/⁻ lymph nodes despite the absence of mature FDCs. Here we show that TNFR1-independent prion accumulation in lymph nodes depends on LTßR signaling. Loss of LTßR signaling, but not of TNFR1, was concurrent with the dedifferentiation of high endothelial venules (HEVs) required for lymphocyte entry into lymph nodes. Using luminescent conjugated polymers for histochemical PrP(Sc) detection, we identified PrP(Sc) deposits associated with HEVs in TNFR1⁻/⁻ lymph nodes. Hence, prions may enter lymph nodes by HEVs and accumulate or replicate in the absence of mature FDCs.


Subject(s)
Dendritic Cells, Follicular/immunology , Lymph Nodes/immunology , Lymphotoxin-alpha/immunology , PrPSc Proteins/immunology , Scrapie/immunology , Tumor Necrosis Factor-alpha/immunology , Animals , Dendritic Cells, Follicular/metabolism , Dendritic Cells, Follicular/pathology , Lymph Nodes/metabolism , Lymph Nodes/pathology , Lymphotoxin beta Receptor/genetics , Lymphotoxin beta Receptor/immunology , Lymphotoxin beta Receptor/metabolism , Lymphotoxin-alpha/genetics , Lymphotoxin-alpha/metabolism , Mice , Mice, Knockout , PrPSc Proteins/genetics , PrPSc Proteins/metabolism , Receptors, Tumor Necrosis Factor, Type I/genetics , Receptors, Tumor Necrosis Factor, Type I/immunology , Receptors, Tumor Necrosis Factor, Type I/metabolism , Scrapie/genetics , Scrapie/metabolism , Scrapie/pathology , Signal Transduction/genetics , Signal Transduction/immunology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
5.
J Med Chem ; 51(12): 3555-61, 2008 Jun 26.
Article in English | MEDLINE | ID: mdl-18507367

ABSTRACT

In this study we investigated the structural requirements for inhibition of human salivary alpha-amylase by flavonoids. Four flavonols and three flavones, out of the 19 flavonoids tested, exhibited IC50 values less than 100 microM against human salivary alpha-amylase activity. Structure-activity relationships of these inhibitors by computational ligand docking showed that the inhibitory activity of flavonols and flavones depends on (i) hydrogen bonds between the hydroxyl groups of the polyphenol ligands and the catalytic residues of the binding site and (ii) formation of a conjugated pi-system that stabilizes the interaction with the active site. Our findings show that certain naturally occurring flavonoids act as inhibitors of human alpha-amylase, which makes them promising candidates for controlling the digestion of starch and postprandial glycemia.


Subject(s)
Flavones/chemistry , Flavonols/chemistry , Models, Molecular , Starch/metabolism , alpha-Amylases/antagonists & inhibitors , Catalytic Domain , Digestion , Humans , Hydrogen Bonding , Ligands , Protein Conformation , Saliva/enzymology , Structure-Activity Relationship , alpha-Amylases/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...